Advocacy for outpatient cardiac rehabilitation globally

BMC Health Services Research

Volumn 16, Issue 1, 2016, Pages

  Babu, Abraham Samuel ^a   Lopez Jimenez, Francisco ^b   Thomas, Randal J ^b   Isaranuwatchai, Wanrudee ^c,d   Herdy, Artur Haddad ^e   Hoch, Jeffrey S ^c,d   Grace, Sherry L ^f,g  

^a MANIPAL UNIVERSITY   (India)

^b MAYO CLINIC   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Universidade e Do sul de Santa Catarina   (Brazil)

^f YORK UNIVERSITY   (Canada)

^g TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Cardiac rehabilitation; Cardiovascular disease; Insurance; Reimbursement

Indexed keywords

AMBULATORY CARE; CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; ECONOMICS; GLOBAL HEALTH; HEALTH CARE COST; HEALTH INSURANCE; HEART REHABILITATION; HUMAN; MALE; OUTPATIENT; PATIENT ADVOCACY; POVERTY; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT;

AMBULATORY CARE; CARDIAC REHABILITATION; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; GLOBAL HEALTH; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH; MALE; OUTPATIENTS; PATIENT ADVOCACY; POVERTY; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; REIMBURSEMENT MECHANISMS;

EID: 84986252343     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-016-1658-1     Document Type: Review

References (53)

1. World Health Organization; World Heart Federation; World Stroke Organization. Global atlas on CVD prevention and control. Geneva: WHO; 2011. http://www.who.int/cardiovascular-diseases/publications/atlas-cvd/en/. Accessed 24 Sept 2015.
2. Bloom DE, Cafiero, ET, Jané-Llopis E, Abrahams-Gessel S, Bloom, LR, Fathima, S, et al. The World Economic Forum and Harvard School of Public Health. The global economic burden of non-communicable diseases. 2011. http://www3.weforum.org/docs/WEF-Harvard-HE-GlobalEconomicBurdenNonCommunicableDiseases-2011.pdf. Accessed 24 Sept 2015
3. World Health Organization. The global burden of disease: 2004 update. http://www.who.int/healthinfo/global-burden-disease/2004-report-update/en/.Accessed 29 Sept 2015.
4. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197-223.
5. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163-96.
6. World Health Organization. Rehabilitation after cardiovascular disease with special emphasis on developing countries. WHO Technical Report Series No. 831. Geneva: WHO; 1993. http://apps.who.int/iris/bitstream/10665/38455/1/WHO-TRS-831.pdf Accessed 28 Sept 2015.
7. Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JM, et al. Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update. Circulation. 2007;115:2675-82.
8. American Association of Cardiovascular and Pulmonary Rehabilitation. Guidelines for Cardiac Rehabilitation and Secondary Prevention Programs. 5th ed. Human Kinetics: USA; 2013.
9. Buckley JP, Furze G, Doherty P, Speck L, Connolly S, Hinton S, et al. British Association of Cardiovascular Prevention and Rehabilitation scientific statement: British standards and core components for cardiovascular disease prevention and rehabilitation. Heart. 2013;99:1069-71.
10. Woodruffe S, Neubeck L, Clark RA, Gray K, Ferry C, Finan J, et al. Australian Cardiovascular Health and Rehabilitation Association (ACRA) Core Components of Cardiovascular Disease Secondary Prevention and Cardiac Rehabilitation 2014. Heart Lung Circ. 2015;24:430-41.
11. Piepoli MF, Corrà U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol. 2014;21:664-81.
12. Pavy B, Iliou MC, Vergès-Patois B, Brion R, Monpère C, Carré F, et al. Exercise, Rehabilitation Sport Group (GERS); French Society of Cardiology. French Society of Cardiology guidelines for cardiac rehabilitation in adults. Arch Cardiovasc Dis. 2012;105:309-28.
13. Grace SL, Warburton DER, Stone JA, Sanderson B, Oldridge N, Jones J, et al. International charter on cardiovascular prevention and rehabilitation: A call for action. J Cardiopulm Rehabil Prev. 2013;33:128-31.
14. Turk-Adawi K, Grace SL. Narrative review comparing the benefits of, participation cardiac rehabilitation in high-, middle- and low-income countries. Heart Lung Circ. 2015;24:510-20.
15. Anderson L, Taylor RS. Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2014;12:CD011273.
16. Thakur JS, Prinja S, Garg C, Mendis S, Menabde N. Social and economic implications of non-communicable diseases in India. Indian J Community Med. 2011;36(suppl):S13-22.
17. Turk-Adawi K, Sarrafzadegan N, Grace SL. Global availability of cardiac rehabilitation. Nat Rev Cardiol. 2014;11:586-96.
18. Anchique Santos CV, Lopez-Jimenez F, Benaim B, Burdiat G, Fernandez Coronado R, Gonzalez G, et al. Cardiac rehabilitation in Latin America. Prog Cardiovasc Dis. 2014;57:268-75.
19. Cortes-Bergoderi M, Lopez-Jimenez F, Herdy AH, Zeballos C, Anchique C, Santibañez C, et al. Availability and characteristics of cardiovascular rehabilitation programs in South America. J Cardiopulm Rehabil Prev. 2013;33:33-41.
20. Tramarin R, Ambrosetti M, De Feo S, Piepoli M, Riccio C. Griffo R; ISYDE-208 Investigators of the Italian Association for Cardiovascular Prevention, Rehabilitation and Prevention. The Italian Survey on Cardiac Rehabilitation-2008 (ISYDE-2008). Part 3. National availability and organization of cardiac rehabilitation facilities. Official report of the Italian Association for Cardiovascular Prevention, Rehabilitation and Epidemiology (IACPR-GICR). Monaldi Arch Chest Dis. 2008;70:175-205.
21. Curnier DY, Savage PD, Ades PA. Geographic distribution of cardiac rehabilitation programs in the United States. J Cardiopulm Rehabil. 2005;25:80-4.
22. Suaya J, Shepard D, Normand S, Ades P, Prottas J, Stason W. Use of cardiac rehabilitation by Medicare beneficiaries after myocardial infarction or coronary bypass surgery. Circulation. 2007;116:1653-62.
23. Kotseva K, Wood D, Backer GD, Bacquer DD. Use and effects of cardiac rehabilitation in patients with coronary heart disease: results from the EUROASPIRE III survey. Eur J Prev Cardiol. 2013;20:817-26.
24. Grace SL, Gravely-Witte S, Brual J, Monette G, Suskin N, Higginson L, et al. Contribution of patient and physician factors to cardiac rehabilitation enrollment: a prospective multilevel study. Eur J Cardiovasc Prev Rehabil. 2008;15:548-56.
25. Levin LA, Perk J, Hedback B. Cardiac rehabilitation - a cost analysis. J Inten Med. 1991;230:427-34.
26. Bjarnason- Wehrens B, McGee H, Zwisler AD, Piepoli M, Benzer W, Schmid JP, et al. Cardiac rehabilitation in Europe: Results from the European cardiac rehabilitation inventory survey. Eur J Cardiovasc Prev Rehabil. 2010;17:410-8.
27. Suaya JA, Stason WB, Ades PA, Normand S-LT, Shepard DS. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol. 2009;54:25-33.
28. Stewart R, Held C, Brown R, Vedin O, Hagstrom E, Lonn E, et al. Physical activity in patients with stable coronary heart disease: An international perspective. Eur Heart J. 2013;34:3286-93.
29. Thirapatarapong W, Thomas RJ, Pack Q, Sharma S, Squires RW. Commercial insurance coverage for outpatient cardiac rehabilitation in patients with heart failure in the United States. J Cardiopulm Rehabil Prev. 2014;34:386-9.
30. Merrian Webster. http://www.merriam-webster.com/dictionary/advocacy Accessed 24 Sept 2015.
31. Zoghbi WA, Duncan T, Antman E, Barbosa M, Champagne B, Chen D, et al. Sustainable development goals and the future of cardiovascular health: a statement from the Global Cardiovascular Disease Taskforce. Glob Heart. 2014;9:273-4.
32. United Nations General Assembly. Open working group on Sustainable Developmental Goals. Geneva; 2014. https://sustainabledevelopment.un.org/sdgsproposal Accessed 26 Sept 2015.
33. Wong WP, Feng J, Pwee KH, Lim J. A systematic review of economic evaluations of cardiac rehabilitation. BMC Health Serv Res. 2012;12:243.
34. Oldridge N. Exercise-based cardiac rehabilitation in patients with coronary heart disease: meta-analysis outcomes revisited. Future Cardiol. 2012;8:729-51.
35. American Association for Cardiovascular and Pulmonary Rehabilitation. https://www.aacvpr.org/Advocacy. Accessed 24 Sept 2015
36. World Heart Federation. http://www.world-heart-federation.org/what-we-do/advocacy/advocacy-toolkit/Accessed 24 Sept 2015
37. Public Health Agency of Canada. Economic burden of illness in Canada, 2005-2008. Ministry of Health, 2014. http://www.phac-aspc.gc.ca/publicat/ebic-femc/2005-2008/assets/pdf/ebic-femc-2005-2008-eng.pdf. Accessed 24 Sept 2015
38. Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Gray A, Scarborough P, Rayner M. European cardiovascular disease statistics. Sophia Antipolis: European Heart Network, Brussels, European Society of Cardiology; 2010.
39. Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27:1610-9.
40. Trogdon JG, Finkelstein EA, Nwaise IA, Tangka FK, Orenstein D. The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract. 2007;8:234-42.
41. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007;370:1929-38.
42. Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff (Millwood). 2007;26:13-24.
43. Sloan FA, Detsky AS, Kaplan RM, Dranove D, Weinstein MC, Pauly MV, et al. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies. Sloan: Cambridge University Press; 1996.
44. Dunlay SM, Pack QR, Thomas RJ, Killian JM, Roger VL. Participation in cardiac rehabilitation, readmissions, and death after acute myocardial infarction. Am J Med. 2014;127:538-46.
45. Engblom E, Korpilahti K, Hämäläinen H, Rönnemaa T, Puukka P. Quality of life and return to work 5 years after coronary artery bypass surgery. Long-term results of cardiac rehabilitation. J Cardiopulm Rehabil. 1997;17:29-36.
46. Ades PA, Pashkow FJ, Nestor JR. Cost-effectiveness of cardiac rehabilitation after myocardial infarction. J Cardiopulm Rehabil Prev. 1997;17:222-31.
47. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997;336:332-6.
48. Cleland JG, Walker A. Is medical treatment for angina the most cost-effective option? Eur Heart J. 1997;18(Suppl B):B35-42.
49. Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation. 2007;115:2398-409.
50. Dendale P, Hansen D, Berger J, Lamotte M. Long-term cost-benefit ratio of cardiac rehabilitation after percutaneous coronary intervention. Acta Cardiol. 2008;63:451-6.
51. Weintraub WS, Boden WE, Zhang Z, et al. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008;1:12-20.
52. Wilson K, Hettle R, Marbaix S, Diaz Cerezo S, Ines M, Santoni L, et al. An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy. Eur J Prev Cardiol. 2012;19:1173-83.
53. Smith T, Jordaens L, Theuns DA, van Dessel PF, Wilde AA, Hunink MG. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. Eur Heart J. 2013;34:211-9.